Brief: SynAct Pharma Q4 Sales SEK 0
18/02/2026 06:30
Feb 18 (Reuters) - SynAct Pharma Q4 net income SEK -22.929 million. Q4 adjusted EPS SEK -0.43 Q4 operating expenses SEK 22.72 million Q4 cash flow from operating activities SEK -23.965 million
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development